JP2540017B2 - ５−ｈｔ１−様作用薬としてのインド―ル誘導体 - Google Patents

５−ｈｔ１−様作用薬としてのインド―ル誘導体

Info

Publication number
JP2540017B2
JP2540017B2 JP5517960A JP51796093A JP2540017B2 JP 2540017 B2 JP2540017 B2 JP 2540017B2 JP 5517960 A JP5517960 A JP 5517960A JP 51796093 A JP51796093 A JP 51796093A JP 2540017 B2 JP2540017 B2 JP 2540017B2
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
optionally
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP5517960A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07502537A (ja
Inventor
ブラウン，アラン・ダニエル
ディッキンソン，ロジャー・ピーター
ウィスィーズ，マーティン・ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Original Assignee
Pfizer Corp Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium filed Critical Pfizer Corp Belgium
Publication of JPH07502537A publication Critical patent/JPH07502537A/ja
Application granted granted Critical
Publication of JP2540017B2 publication Critical patent/JP2540017B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP5517960A 1992-04-14 1993-04-08 ５−ｈｔ１−様作用薬としてのインド―ル誘導体 Expired - Lifetime JP2540017B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9208161.1 1992-04-14
GB929208161A GB9208161D0 (en) 1992-04-14 1992-04-14 Indoles

Publications (2)

Publication Number Publication Date
JPH07502537A JPH07502537A (ja) 1995-03-16
JP2540017B2 true JP2540017B2 (ja) 1996-10-02

Family

ID=10713993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5517960A Expired - Lifetime JP2540017B2 (ja) 1992-04-14 1993-04-08 ５−ｈｔ１−様作用薬としてのインド―ル誘導体

Country Status (12)

Country Link
US (1) US5502065A (enExample)
EP (1) EP0636129A1 (enExample)
JP (1) JP2540017B2 (enExample)
CN (1) CN1082040A (enExample)
AU (1) AU3952693A (enExample)
CA (1) CA2117498A1 (enExample)
FI (1) FI944805A7 (enExample)
GB (1) GB9208161D0 (enExample)
IL (1) IL105312A0 (enExample)
TW (1) TW224095B (enExample)
WO (1) WO1993021178A1 (enExample)
ZA (1) ZA932582B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
CA2138649A1 (en) * 1992-07-24 1994-02-03 Raymond Baker Imidazole, triazole and tetrazole derivatives
AU686654B2 (en) * 1993-08-31 1998-02-12 Pfizer Inc. 5-arylindole derivatives
ES2079323B1 (es) * 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
FR2737721B1 (fr) * 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
US5770742A (en) * 1996-05-16 1998-06-23 Allelix Biopharmaceuticals Inc. Thiophene-tryptamine derivatives
CA2253941A1 (en) * 1996-05-16 1997-11-20 Sumanas Rakhit Thiophene- and furan-tryptamine derivatives
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
HUE035130T2 (en) 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv A method for preparing compounds useful as SGLT inhibitors
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
HRP20170446T1 (hr) 2009-10-14 2017-05-19 Janssen Pharmaceutica Nv Postupak pripreme spojeva korisnih kao inhibitori sglt2
AR081036A1 (es) 2010-05-11 2012-05-30 Janssen Pharmaceutica Nv Formulaciones farmaceuticas para tratar enfermedades relacionadas con el transportador de glucosa dependiente de sodio
WO2012004811A1 (en) * 2010-07-06 2012-01-12 Ind-Swift Laboratories Limited Process for the preparation of 5-substsituted indole derivative
KR101913587B1 (ko) 2011-04-13 2018-10-31 얀센 파마슈티카 엔.브이. Sglt2의 억제제로서 유용한 화합물의 제조 방법
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9550750B2 (en) * 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP2019502761A (ja) * 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
ATE204275T1 (de) * 1990-06-07 2001-09-15 Astrazeneca Ab Indolderivate als 5-ht1-like agonisten
BR9106978A (pt) * 1990-10-15 1993-09-28 Pfizer Derivados de indol

Also Published As

Publication number Publication date
TW224095B (enExample) 1994-05-21
AU3952693A (en) 1993-11-18
GB9208161D0 (en) 1992-05-27
FI944805A0 (fi) 1994-10-12
EP0636129A1 (en) 1995-02-01
ZA932582B (en) 1994-10-13
IL105312A0 (en) 1993-08-18
FI944805A7 (fi) 1994-10-12
CN1082040A (zh) 1994-02-16
WO1993021178A1 (en) 1993-10-28
US5502065A (en) 1996-03-26
CA2117498A1 (en) 1993-10-28
JPH07502537A (ja) 1995-03-16

Similar Documents

Publication Publication Date Title
JP2540017B2 (ja) ５−ｈｔ１−様作用薬としてのインド―ル誘導体
JP3499243B2 (ja) タキキニンアンタゴニストとしてのベンゾフラン誘導体
AU693936B2 (en) Novel substituted piperidines useful for the treatment of allergic diseases
JP7446316B2 (ja) 置換ピロリジンアミドｉｉｉ
JP2786480B2 (ja) １―インドリルアルキル―４―（置換ピリジニル）ピペラジン
AU742077B2 (en) Anilide derivative, production and use thereof
JP2867151B2 (ja) ビペリジニルベンズイミダゾール類
JP3148254B2 (ja) 置換インダゾール誘導体、並びにホスホジエステラーゼ（ｐｄｅ）ｉｖ型及び腫瘍壊死因子（ｔｎｆ）産性の阻害剤
JPH05262762A (ja) インドール−３イル−アルキルピペラジンの抗偏頭痛４−ピロミジニル及びピリジニル誘導体
JPH07505648A (ja) アザサイクリック化合物
EP0464604B1 (en) 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines
JP2006514656A (ja) Ｃｂ１／ｃｂ２受容体リガンドおよび疼痛の治療におけるその使用
ZA200602448B (en) Thrombin receptor antagonists
JPWO1994007890A1 (ja) ピリミジン化合物
JPH07504919A (ja) ５−ｈｔ１作動薬としてのインドール誘導体
US5998438A (en) 5-cyclo indole compounds
WO2000039097A1 (en) Imidazole compounds and medicinal use thereof
TW202208351A (zh) 作為組蛋白去乙醯酶6抑制劑之新穎化合物及包含其之醫藥組合物
JP2784265B2 (ja) ５−ｈｔ▲下１▼様アゴニストとしてのインドール誘導体
JPH11513991A (ja) アレルギー性疾患の治療に有用な置換４−（１ｈ−ベンズイミダゾル−２−イル−アミノ）ピペリジン
IE920365A1 (en) Platelet activatng factor antagonists
JPH11263764A (ja) アニリド誘導体、その製造法および用途
EP0882038B1 (en) substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
WO1998058930A1 (en) Triazolo-1,4-diazepine compounds and medicinal composition containing the same
AU2002359378B2 (en) Isochroman compounds for treatment of CNS disorders